Evidence map›Paper›PMID 38163281›Full record

SynthesisJournal of medical virology2024

Vaccination against influenza viruses reduces infection, not hospitalization or death, from respiratory COVID-19: A systematic review and meta-analysis.

Antonio E Pontiroli, Francesco Scovenna, Valentina Carlini, Elena Tagliabue, Jimmy Martin-Delgado, Lucia La Sala, Elisabetta Tanzi, Ivan Zanoni

Open access · bronzeAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Journal of medical virology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Antonio E PontiroliDipartimento di Scienze della Salute, Università degli Studi di Milano, Milan, Italy.ORCID 0000-0002-8217-7672
Francesco ScovennaDipartimento di Scienze della Salute, Università degli Studi di Milano, Milan, Italy.
Valentina CarliniLaboratory of Cardiovascular and Dysmetabolic Disease, IRCCS MultiMedica, Milan, Italy.
Elena TagliabueIRCCS MultiMedica, Value-Based Healthcare Unit, Milan, Italy.
Jimmy Martin-DelgadoHospital Luis Vernaza, Junta de Beneficiencia de Guayaquil, Guayaquil, Ecuador.ORCID 0000-0003-4384-9197
Lucia La SalaLaboratory of Cardiovascular and Dysmetabolic Disease, IRCCS MultiMedica, Milan, Italy.
Elisabetta TanziDipartimento di Scienze della Salute, Università degli Studi di Milano, Milan, Italy.ORCID 0000-0002-4119-701X
Ivan ZanoniHarvard Medical School, Division of Immunology and Division of Gastroenterology, Boston Children's Hospital, Boston, Massachusetts, USA.
University of Milan · ITMultiMedica · ITBoston Children's Hospital · USUniversidad Católica de Santiago de Guayaquil · EC

Funding

Small-molecule adjuvants to enhance the efficacy of flu vaccines in newborns and the elderly75N93019C00044 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI LEVY, OFER · 2019 to 2023
$11.0M
Type III interferon Control of Mucosal ImmunityR01DK115217 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI Scott B Snapper, Ivan Zanoni · 2017 to 2026
$5.6M
Innate control of the inflammatory process during fungal infectionsR01AI121066 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI ZANONI, IVAN · 2016 to 2025
$4.8M
Development of a novel adjuvant strategy enabled by modulation of the physical properties of fungal mannansR01AI165505 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI Ivan Zanoni · 2021 to 2026
$4.6M
Macrophage immunometabolism controls septic shockR01AI170632 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI Ivan Zanoni · 2023 to 2026
$2.5M
NIAID NIH HHS 75N93019C00044NIAID NIH HHS R01 AI121066NIAID NIH HHS R01 AI165505NIAID NIH HHS R01 AI170632NIDDK NIH HHS R01 DK115217NIH HHSNIH HHS 1R01AI165505NIH HHS 1R01AI170632NIH HHS 2R01AI121066NIH HHS 2R01DK115217
6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19 and has brought a huge burden in terms of human lives. Strict social distance and influenza vaccination have been recommended to avoid co-infections between influenza viruses and SARS-CoV-2. Scattered reports suggested a protective effect of influenza vaccine on COVID-19 development and severity. We analyzed 51 studies on the capacity of influenza vaccination to affect infection with SARS-CoV-2, hospitalization, admission to Intensive Care Units (ICU), and mortality. All subjects taken into consideration did not receive any anti-SARS-CoV-2 vaccine, although their status with respect to previous infections with SARS-CoV-2 is not known. Comparison between vaccinated and not-vaccinated subjects for each of the four endpoints was expressed as odds ratio (OR), with 95% confidence intervals (CIs); all analyses were performed by DerSimonian and Laird model, and Hartung-Knapp model when studies were less than 10. In a total of 61 029 936 subjects from 33 studies, influenza vaccination reduced frequency of SARS-CoV-2 infection [OR plus 95% CI = 0.70 (0.65-0.77)]. The effect was significant in all studies together, in health care workers and in the general population; distance from influenza vaccination and the type of vaccine were also of importance. In 98 174 subjects from 11 studies, frequency of ICU admission was reduced with influenza vaccination [OR (95% CI) = 0.71 (0.54-0.94)]; the effect was significant in all studies together, in pregnant women and in hospitalized subjects. In contrast, in 4 737 328 subjects from 14 studies hospitalization was not modified [OR (95% CI) = 1.05 (0.82-1.35)], and in 4 139 660 subjects from 19 studies, mortality was not modified [OR (95% CI) = 0.76 (0.26-2.20)]. Our study emphasizes the importance of influenza vaccination in the protection against SARS-CoV-2 infection.

Indexed as

COVID-19Influenza VaccinesFemaleHospitalizationHumansInfluenza, HumanPregnancySARS-CoV-2VaccinationInfluenza Vaccinescovid-19epidemiologyhospitalizationinfectioninfluenzainfluenza vaccinationinfluenza vaccineintensive care unitsmeta-analysismortalitysars-cov-2vaccines

Identifiers

PMID38163281
PMCPMC10924223
OpenAlexW4390478492

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.